A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2011-12

AUTHORS

Annick Desjardins, David A. Reardon, Katherine B. Peters, Stevie Threatt, April D. Coan, James E. Herndon, Allan H. Friedman, Henry S. Friedman, James J. Vredenburgh

ABSTRACT

We conducted a phase I clinical trial of the combination of SCH 66336 with temozolomide administered on the standard 5-day dosing schedule. The primary objective was to determine the maximum tolerated dose and dose limiting toxicity (DLT) of twice daily SCH 66336 when administered with temozolomide to adults with malignant glioma previously treated with radiation therapy. Patients were enrolled to two strata: stratum A, patients not on enzyme-inducing antiepileptic drugs (EIAEDs); stratum B, patients receiving EIAEDs. Temozolomide was administered at a dose of 150 mg/m(2) daily for five days for the first 28-day cycle and escalated to 200 mg/m(2), during subsequent cycles. SCH 66336 was administered twice daily on a continuous daily dosing schedule. The starting dose of SCH 66336 was 75 mg twice daily for stratum A and 125 mg twice daily for stratum B. Cohorts of 3-6 patients were treated per dose level until DLT was observed. Thirty six patients were enrolled on study, including 21 patients on stratum A and 15 on stratum B. All DLTs were grade 3 events and included hepatic, gastrointestinal, renal, thrombotic and constitutional events. No grade 4 or 5 toxicities were observed. The phase II dose of SCH 66336 when combined with temozolomide is 150 mg twice daily for patients not on EIAEDs and 175 mg twice daily for patients on EIAEDs. More... »

PAGES

601-606

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11060-011-0627-0

DOI

http://dx.doi.org/10.1007/s11060-011-0627-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1031938716

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/21735117


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Brain Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carotenoids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dacarbazine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Combinations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enzyme Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fatty Acids, Unsaturated", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glioma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Maximum Tolerated Dose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Grading", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Piperidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyridines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vitamin E", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, 27710, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Desjardins", 
        "givenName": "Annick", 
        "id": "sg:person.0701277507.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0701277507.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, 27710, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Reardon", 
        "givenName": "David A.", 
        "id": "sg:person.01334047606.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334047606.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, 27710, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Peters", 
        "givenName": "Katherine B.", 
        "id": "sg:person.0744714665.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744714665.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, 27710, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Threatt", 
        "givenName": "Stevie", 
        "id": "sg:person.01311712043.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01311712043.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.414179.e", 
          "name": [
            "Department of Biostatistics and Bioinformatics, Duke University Medical Center, 27710, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Coan", 
        "givenName": "April D.", 
        "id": "sg:person.01120050567.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01120050567.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.414179.e", 
          "name": [
            "Department of Biostatistics and Bioinformatics, Duke University Medical Center, 27710, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Herndon", 
        "givenName": "James E.", 
        "id": "sg:person.01175371665.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01175371665.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, 27710, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Friedman", 
        "givenName": "Allan H.", 
        "id": "sg:person.01167656444.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167656444.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, 27710, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Friedman", 
        "givenName": "Henry S.", 
        "id": "sg:person.01333344755.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333344755.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, 27710, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vredenburgh", 
        "givenName": "James J.", 
        "id": "sg:person.013241345417.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013241345417.00"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1074/jbc.m503763200", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005457814"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.m503763200", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005457814"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ijc.11064", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006472234"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-06-1262", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014070179"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1991.54", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017208276", 
          "https://doi.org/10.1038/bjc.1991.54"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1991.54", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017208276", 
          "https://doi.org/10.1038/bjc.1991.54"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.22901", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017566383"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-03-0412", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019198461"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1750-3639.2003.tb00006.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019823010"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1017/s0317167100034272", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027962724"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1203105", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028710865", 
          "https://doi.org/10.1038/sj.onc.1203105"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1203105", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028710865", 
          "https://doi.org/10.1038/sj.onc.1203105"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-010-1488-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031662375", 
          "https://doi.org/10.1007/s00280-010-1488-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-007-0646-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038092295", 
          "https://doi.org/10.1007/s00280-007-0646-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-007-0646-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038092295", 
          "https://doi.org/10.1007/s00280-007-0646-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/(sici)1097-0215(19990331)81:1<118::aid-ijc20>3.0.co;2-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042598668"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1201455", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045026279", 
          "https://doi.org/10.1038/sj.onc.1201455"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1201455", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045026279", 
          "https://doi.org/10.1038/sj.onc.1201455"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa043330", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052112015"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00006123-199912000-00034", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060250470"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074813249", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1076575034", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1990.8.7.1277", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1078716995"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079010052", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-12", 
    "datePublishedReg": "2011-12-01", 
    "description": "We conducted a phase I clinical trial of the combination of SCH 66336 with temozolomide administered on the standard 5-day dosing schedule. The primary objective was to determine the maximum tolerated dose and dose limiting toxicity (DLT) of twice daily SCH 66336 when administered with temozolomide to adults with malignant glioma previously treated with radiation therapy. Patients were enrolled to two strata: stratum A, patients not on enzyme-inducing antiepileptic drugs (EIAEDs); stratum B, patients receiving EIAEDs. Temozolomide was administered at a dose of 150 mg/m(2) daily for five days for the first 28-day cycle and escalated to 200 mg/m(2), during subsequent cycles. SCH 66336 was administered twice daily on a continuous daily dosing schedule. The starting dose of SCH 66336 was 75 mg twice daily for stratum A and 125 mg twice daily for stratum B. Cohorts of 3-6 patients were treated per dose level until DLT was observed. Thirty six patients were enrolled on study, including 21 patients on stratum A and 15 on stratum B. All DLTs were grade 3 events and included hepatic, gastrointestinal, renal, thrombotic and constitutional events. No grade 4 or 5 toxicities were observed. The phase II dose of SCH 66336 when combined with temozolomide is 150 mg twice daily for patients not on EIAEDs and 175 mg twice daily for patients on EIAEDs.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s11060-011-0627-0", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094205", 
        "issn": [
          "0167-594X", 
          "1573-7373"
        ], 
        "name": "Journal of Neuro-Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "105"
      }
    ], 
    "name": "A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma", 
    "pagination": "601-606", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "98266bea51c605ea0eed7892b2699381b7622e73556d2ca2dad42a00ea9d8a3b"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "21735117"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309335"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11060-011-0627-0"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1031938716"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11060-011-0627-0", 
      "https://app.dimensions.ai/details/publication/pub.1031938716"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T20:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8681_00000533.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs11060-011-0627-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11060-011-0627-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11060-011-0627-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11060-011-0627-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11060-011-0627-0'


 

This table displays all metadata directly associated to this object as RDF triples.

271 TRIPLES      21 PREDICATES      69 URIs      42 LITERALS      30 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11060-011-0627-0 schema:about N151d232d77df419cbde1e357215d1174
2 N1881a04245cd4a4e9260a7ffe67fe7f6
3 N3aac452dbb80424e8b9e9e40ddc187aa
4 N3d0fe66799d74db883aa875b82e48aa4
5 N4a6ffebc8c22400fa8b05ec4832dab7d
6 N4b1776e9ff5c4867b28b3d597c95a088
7 N57d4536db4834b9bbf1f6099f4a4568b
8 N769c24900ca94e77ac7df984bbf66781
9 N7d113cbc619e41ac8fd57752ff3c882f
10 N8f32abb471ff4664a0d028287e2d9d25
11 N9399f9eba19d49489789048abd83f65d
12 N9bd725a736df4f73985d50c00d2a7c6a
13 Nc10bca1fea824158aa5ad7a5de67174b
14 Nd0c85c33b90f400a823a6e819469495c
15 Nd16d276d84534c499ee31e95059b8277
16 Nda53a68b96b94a61a5e77685f5055fbb
17 Ndddd776d35874480a59846f1f74e2c54
18 Ne24a6344654440749821e48ac7ba9c6a
19 Ne432ed193b76493a9c38e66d1880564f
20 Ne53f292b333a4b4f84ac4eab7dc6a4de
21 Nec1e35be14a44e6ca580170ada6d82d6
22 anzsrc-for:11
23 anzsrc-for:1115
24 schema:author Nd7c47192e4a648249a94b6bf65c35311
25 schema:citation sg:pub.10.1007/s00280-007-0646-x
26 sg:pub.10.1007/s00280-010-1488-5
27 sg:pub.10.1038/bjc.1991.54
28 sg:pub.10.1038/sj.onc.1201455
29 sg:pub.10.1038/sj.onc.1203105
30 https://app.dimensions.ai/details/publication/pub.1074813249
31 https://app.dimensions.ai/details/publication/pub.1076575034
32 https://app.dimensions.ai/details/publication/pub.1079010052
33 https://doi.org/10.1002/(sici)1097-0215(19990331)81:1<118::aid-ijc20>3.0.co;2-5
34 https://doi.org/10.1002/cncr.22901
35 https://doi.org/10.1002/ijc.11064
36 https://doi.org/10.1017/s0317167100034272
37 https://doi.org/10.1056/nejmoa043330
38 https://doi.org/10.1074/jbc.m503763200
39 https://doi.org/10.1097/00006123-199912000-00034
40 https://doi.org/10.1111/j.1750-3639.2003.tb00006.x
41 https://doi.org/10.1158/1078-0432.ccr-03-0412
42 https://doi.org/10.1158/1078-0432.ccr-06-1262
43 https://doi.org/10.1200/jco.1990.8.7.1277
44 schema:datePublished 2011-12
45 schema:datePublishedReg 2011-12-01
46 schema:description We conducted a phase I clinical trial of the combination of SCH 66336 with temozolomide administered on the standard 5-day dosing schedule. The primary objective was to determine the maximum tolerated dose and dose limiting toxicity (DLT) of twice daily SCH 66336 when administered with temozolomide to adults with malignant glioma previously treated with radiation therapy. Patients were enrolled to two strata: stratum A, patients not on enzyme-inducing antiepileptic drugs (EIAEDs); stratum B, patients receiving EIAEDs. Temozolomide was administered at a dose of 150 mg/m(2) daily for five days for the first 28-day cycle and escalated to 200 mg/m(2), during subsequent cycles. SCH 66336 was administered twice daily on a continuous daily dosing schedule. The starting dose of SCH 66336 was 75 mg twice daily for stratum A and 125 mg twice daily for stratum B. Cohorts of 3-6 patients were treated per dose level until DLT was observed. Thirty six patients were enrolled on study, including 21 patients on stratum A and 15 on stratum B. All DLTs were grade 3 events and included hepatic, gastrointestinal, renal, thrombotic and constitutional events. No grade 4 or 5 toxicities were observed. The phase II dose of SCH 66336 when combined with temozolomide is 150 mg twice daily for patients not on EIAEDs and 175 mg twice daily for patients on EIAEDs.
47 schema:genre research_article
48 schema:inLanguage en
49 schema:isAccessibleForFree false
50 schema:isPartOf N91f341153cc24c63ae11ced7c0609eeb
51 Nd52fb854fb694ad4ad473b85b23a976e
52 sg:journal.1094205
53 schema:name A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma
54 schema:pagination 601-606
55 schema:productId N2235290cef7c4f2da7dc47d13a0e840d
56 N269b282170f443f5ab25788135a258d6
57 N3e1f83f2adbb4378b0dd6dbea3ce656e
58 Na4fd54db85a94881b39b15bd6f660d8f
59 Nacedbc7ed3d448dc87af44f33f6b7cb4
60 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031938716
61 https://doi.org/10.1007/s11060-011-0627-0
62 schema:sdDatePublished 2019-04-10T20:01
63 schema:sdLicense https://scigraph.springernature.com/explorer/license/
64 schema:sdPublisher N2e57344778d3447abc1a99b47ed1a696
65 schema:url http://link.springer.com/10.1007%2Fs11060-011-0627-0
66 sgo:license sg:explorer/license/
67 sgo:sdDataset articles
68 rdf:type schema:ScholarlyArticle
69 N0f3e1b3ae5be4e4cbe7af5ff6c44bebf rdf:first sg:person.0744714665.06
70 rdf:rest N7ce7773736d4427cb3233f42a5cbcf63
71 N151d232d77df419cbde1e357215d1174 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Fatty Acids, Unsaturated
73 rdf:type schema:DefinedTerm
74 N1881a04245cd4a4e9260a7ffe67fe7f6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Antineoplastic Combined Chemotherapy Protocols
76 rdf:type schema:DefinedTerm
77 N2235290cef7c4f2da7dc47d13a0e840d schema:name doi
78 schema:value 10.1007/s11060-011-0627-0
79 rdf:type schema:PropertyValue
80 N269b282170f443f5ab25788135a258d6 schema:name pubmed_id
81 schema:value 21735117
82 rdf:type schema:PropertyValue
83 N2e57344778d3447abc1a99b47ed1a696 schema:name Springer Nature - SN SciGraph project
84 rdf:type schema:Organization
85 N3aac452dbb80424e8b9e9e40ddc187aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Female
87 rdf:type schema:DefinedTerm
88 N3d0fe66799d74db883aa875b82e48aa4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Enzyme Inhibitors
90 rdf:type schema:DefinedTerm
91 N3e1f83f2adbb4378b0dd6dbea3ce656e schema:name readcube_id
92 schema:value 98266bea51c605ea0eed7892b2699381b7622e73556d2ca2dad42a00ea9d8a3b
93 rdf:type schema:PropertyValue
94 N4a6ffebc8c22400fa8b05ec4832dab7d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Pyridines
96 rdf:type schema:DefinedTerm
97 N4b1776e9ff5c4867b28b3d597c95a088 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Disease-Free Survival
99 rdf:type schema:DefinedTerm
100 N57d4536db4834b9bbf1f6099f4a4568b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Brain Neoplasms
102 rdf:type schema:DefinedTerm
103 N61de797d53cf4bb79678ed376e8dcfb1 rdf:first sg:person.01333344755.48
104 rdf:rest Ne29c37fe12e34b2b85c4008753f5c0e1
105 N743654b637604c459613c4f140a05605 rdf:first sg:person.01120050567.78
106 rdf:rest Nffa6470c34124232a2c34025b656d868
107 N769c24900ca94e77ac7df984bbf66781 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Maximum Tolerated Dose
109 rdf:type schema:DefinedTerm
110 N7ce7773736d4427cb3233f42a5cbcf63 rdf:first sg:person.01311712043.25
111 rdf:rest N743654b637604c459613c4f140a05605
112 N7d113cbc619e41ac8fd57752ff3c882f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Glioma
114 rdf:type schema:DefinedTerm
115 N8f32abb471ff4664a0d028287e2d9d25 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Carotenoids
117 rdf:type schema:DefinedTerm
118 N91f341153cc24c63ae11ced7c0609eeb schema:volumeNumber 105
119 rdf:type schema:PublicationVolume
120 N9399f9eba19d49489789048abd83f65d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Vitamin E
122 rdf:type schema:DefinedTerm
123 N9bd725a736df4f73985d50c00d2a7c6a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Humans
125 rdf:type schema:DefinedTerm
126 Na4fd54db85a94881b39b15bd6f660d8f schema:name dimensions_id
127 schema:value pub.1031938716
128 rdf:type schema:PropertyValue
129 Nabc8873427dd4a3badf93532668c037c rdf:first sg:person.01334047606.77
130 rdf:rest N0f3e1b3ae5be4e4cbe7af5ff6c44bebf
131 Nacedbc7ed3d448dc87af44f33f6b7cb4 schema:name nlm_unique_id
132 schema:value 8309335
133 rdf:type schema:PropertyValue
134 Nb9b0d7fa99144300a515236187d53d6a rdf:first sg:person.01167656444.57
135 rdf:rest N61de797d53cf4bb79678ed376e8dcfb1
136 Nc10bca1fea824158aa5ad7a5de67174b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Piperidines
138 rdf:type schema:DefinedTerm
139 Nd0c85c33b90f400a823a6e819469495c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Drug Combinations
141 rdf:type schema:DefinedTerm
142 Nd16d276d84534c499ee31e95059b8277 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Adult
144 rdf:type schema:DefinedTerm
145 Nd52fb854fb694ad4ad473b85b23a976e schema:issueNumber 3
146 rdf:type schema:PublicationIssue
147 Nd7c47192e4a648249a94b6bf65c35311 rdf:first sg:person.0701277507.35
148 rdf:rest Nabc8873427dd4a3badf93532668c037c
149 Nda53a68b96b94a61a5e77685f5055fbb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Aged
151 rdf:type schema:DefinedTerm
152 Ndddd776d35874480a59846f1f74e2c54 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Dacarbazine
154 rdf:type schema:DefinedTerm
155 Ne24a6344654440749821e48ac7ba9c6a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Neoplasm Grading
157 rdf:type schema:DefinedTerm
158 Ne29c37fe12e34b2b85c4008753f5c0e1 rdf:first sg:person.013241345417.00
159 rdf:rest rdf:nil
160 Ne432ed193b76493a9c38e66d1880564f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Middle Aged
162 rdf:type schema:DefinedTerm
163 Ne53f292b333a4b4f84ac4eab7dc6a4de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Kaplan-Meier Estimate
165 rdf:type schema:DefinedTerm
166 Nec1e35be14a44e6ca580170ada6d82d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Male
168 rdf:type schema:DefinedTerm
169 Nffa6470c34124232a2c34025b656d868 rdf:first sg:person.01175371665.07
170 rdf:rest Nb9b0d7fa99144300a515236187d53d6a
171 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
172 schema:name Medical and Health Sciences
173 rdf:type schema:DefinedTerm
174 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
175 schema:name Pharmacology and Pharmaceutical Sciences
176 rdf:type schema:DefinedTerm
177 sg:journal.1094205 schema:issn 0167-594X
178 1573-7373
179 schema:name Journal of Neuro-Oncology
180 rdf:type schema:Periodical
181 sg:person.01120050567.78 schema:affiliation https://www.grid.ac/institutes/grid.414179.e
182 schema:familyName Coan
183 schema:givenName April D.
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01120050567.78
185 rdf:type schema:Person
186 sg:person.01167656444.57 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
187 schema:familyName Friedman
188 schema:givenName Allan H.
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167656444.57
190 rdf:type schema:Person
191 sg:person.01175371665.07 schema:affiliation https://www.grid.ac/institutes/grid.414179.e
192 schema:familyName Herndon
193 schema:givenName James E.
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01175371665.07
195 rdf:type schema:Person
196 sg:person.01311712043.25 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
197 schema:familyName Threatt
198 schema:givenName Stevie
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01311712043.25
200 rdf:type schema:Person
201 sg:person.013241345417.00 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
202 schema:familyName Vredenburgh
203 schema:givenName James J.
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013241345417.00
205 rdf:type schema:Person
206 sg:person.01333344755.48 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
207 schema:familyName Friedman
208 schema:givenName Henry S.
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333344755.48
210 rdf:type schema:Person
211 sg:person.01334047606.77 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
212 schema:familyName Reardon
213 schema:givenName David A.
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334047606.77
215 rdf:type schema:Person
216 sg:person.0701277507.35 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
217 schema:familyName Desjardins
218 schema:givenName Annick
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0701277507.35
220 rdf:type schema:Person
221 sg:person.0744714665.06 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
222 schema:familyName Peters
223 schema:givenName Katherine B.
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744714665.06
225 rdf:type schema:Person
226 sg:pub.10.1007/s00280-007-0646-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1038092295
227 https://doi.org/10.1007/s00280-007-0646-x
228 rdf:type schema:CreativeWork
229 sg:pub.10.1007/s00280-010-1488-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031662375
230 https://doi.org/10.1007/s00280-010-1488-5
231 rdf:type schema:CreativeWork
232 sg:pub.10.1038/bjc.1991.54 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017208276
233 https://doi.org/10.1038/bjc.1991.54
234 rdf:type schema:CreativeWork
235 sg:pub.10.1038/sj.onc.1201455 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045026279
236 https://doi.org/10.1038/sj.onc.1201455
237 rdf:type schema:CreativeWork
238 sg:pub.10.1038/sj.onc.1203105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028710865
239 https://doi.org/10.1038/sj.onc.1203105
240 rdf:type schema:CreativeWork
241 https://app.dimensions.ai/details/publication/pub.1074813249 schema:CreativeWork
242 https://app.dimensions.ai/details/publication/pub.1076575034 schema:CreativeWork
243 https://app.dimensions.ai/details/publication/pub.1079010052 schema:CreativeWork
244 https://doi.org/10.1002/(sici)1097-0215(19990331)81:1<118::aid-ijc20>3.0.co;2-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042598668
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1002/cncr.22901 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017566383
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1002/ijc.11064 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006472234
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1017/s0317167100034272 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027962724
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1056/nejmoa043330 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052112015
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1074/jbc.m503763200 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005457814
255 rdf:type schema:CreativeWork
256 https://doi.org/10.1097/00006123-199912000-00034 schema:sameAs https://app.dimensions.ai/details/publication/pub.1060250470
257 rdf:type schema:CreativeWork
258 https://doi.org/10.1111/j.1750-3639.2003.tb00006.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1019823010
259 rdf:type schema:CreativeWork
260 https://doi.org/10.1158/1078-0432.ccr-03-0412 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019198461
261 rdf:type schema:CreativeWork
262 https://doi.org/10.1158/1078-0432.ccr-06-1262 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014070179
263 rdf:type schema:CreativeWork
264 https://doi.org/10.1200/jco.1990.8.7.1277 schema:sameAs https://app.dimensions.ai/details/publication/pub.1078716995
265 rdf:type schema:CreativeWork
266 https://www.grid.ac/institutes/grid.189509.c schema:alternateName Duke University Hospital
267 schema:name The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, 27710, Durham, NC, USA
268 rdf:type schema:Organization
269 https://www.grid.ac/institutes/grid.414179.e schema:alternateName Duke Medical Center
270 schema:name Department of Biostatistics and Bioinformatics, Duke University Medical Center, 27710, Durham, NC, USA
271 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...